Capricor Therapeutics (NASDAQ:CAPR) Shares Down 9.3% – What’s Next?

Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) were down 9.3% on Tuesday. The company traded as low as $9.02 and last traded at $8.9320. Approximately 3,207,720 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 3,156,311 shares. The stock had previously closed at $9.85.

Analysts Set New Price Targets

Several brokerages have commented on CAPR. HC Wainwright lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, July 27th. Maxim Group downgraded Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Alliance Global Partners cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a research note on Tuesday, July 28th. LADENBURG THALM/SH SH downgraded Capricor Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, July 30th. Finally, B. Riley Financial upgraded Capricor Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $5.00 to $21.00 in a research report on Monday, September 14th. Four analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $30.25.

Capricor Therapeutics Trading Down 9.4%

The stock has a market cap of $518.73 million, a PE ratio of -3.62 and a beta of 0.80. The business’s 50-day moving average price is $8.09 and its 200-day moving average price is $20.13.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). As a group, analysts predict that Capricor Therapeutics, Inc. will post -1.71 earnings per share for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its position in shares of Capricor Therapeutics by 672.0% in the first quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company’s stock valued at $12,631,000 after acquiring an additional 361,664 shares in the last quarter. Montanova Capital LLC boosted its holdings in shares of Capricor Therapeutics by 7.2% during the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company’s stock worth $98,554,000 after purchasing an additional 274,184 shares during the last quarter. Walleye Capital LLC purchased a new stake in shares of Capricor Therapeutics in the first quarter valued at approximately $5,397,000. Bank of New York Mellon Corp acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at approximately $3,895,000. Finally, Oppenheimer & Co. Inc. boosted its position in shares of Capricor Therapeutics by 169.1% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 203,781 shares of the biotechnology company’s stock valued at $1,930,000 after acquiring an additional 128,067 shares during the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage. Capricor’s lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.